SQURPHARMA Square Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 218.8 as of 2026-11-12 14:09:58
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 4 of 4 years
- Consistency Paid a dividend every year (5/5)
- Profitability Average ROE 17.87% (efficient: above 15%)
- Profitability Net profit growing 10.72% a year
- Solvency Practically debt-free (loan risk cannot hurt it)
- Valuation P/E 6.91 is low (general benchmark ≤ 12)
- Valuation Trades near book value (P/NAV 1.17x)
- Valuation Price is 40% below the Graham fair value (Tk 362.9)
Risk flags
No flags raised.
Valuation
52-week range
10.5% above the low, 7.3% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 44.2%
- Institution 13.9%
- Foreign 13.9%
- Public 28%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 17.99 | 102.54 | 1,595 | 60 | 0 |
| 2022 | 20.51 | 116.7 | 1,818 | 100 | 0 |
| 2023 | 21.41 | 129.95 | 1,898 | 105 | 0 |
| 2024 | 23.61 | 142.05 | 2,093 | 110 | 0 |
| 2025 | 27.04 | 157.88 | 2,397 | 120 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 0.4%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.